Agomab Granted U.S. Patent for AGMB-447
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy AGMB?
Agomab announced that the United States Patent and Trademark Office, or USPTO, has granted U.S. Patent No. 12,577,230, covering the composition of matter of AGMB-447, to Agomab. AGMB-447 is the company's investigational inhaled lung-restricted small molecule inhibitor of ALK5, currently in a Phase 1b study for the treatment of Idiopathic Pulmonary Fibrosis. This patent provides intellectual property protection for AGMB-447 in the U.S. through at least 2041, excluding any potential patent term extensions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AGMB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AGMB
Wall Street analysts forecast AGMB stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 10.850
Low
Averages
High
Current: 10.850
Low
Averages
High
About AGMB
Agomab Therapeutics NV is a Belgium-based company. The Company is engaged in research and development services creating therapies for fibrotic and inflammatory diseases. Its activities include discovery research to identify drug candidates that act on pathways involved in fibrosis and tissue repair, such as organ restricted small molecules and growth factor targeting antibodies. The Company also carries out preclinical development, including work on programs, to evaluate drug behavior and readiness before entering human studies. In addition, It conducts clinical development services by sponsoring and managing trials for its pipeline, assessing safety, tolerability, pharmacokinetics, and pharmacodynamics.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Wall Street Analysts Adjust Ratings
- Analyst Rating Updates: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting the latest market perspectives and expectations for these firms.
- Market Dynamics Overview: While specific company names are not mentioned, changes in analyst ratings typically influence investor decisions, potentially leading to price fluctuations in the related stocks.
- Investor Considerations: For those considering buying AMLX stock, analysts' opinions will serve as a crucial reference point, potentially impacting their investment strategies and market confidence.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions, although specific rating details are not disclosed.
See More
Jennifer Garner's Once Upon a Farm Sees Nearly 20% Increase as IPO Week Concludes
Jennifer Garner's Characters: Garner is known for her roles as Sidney Bristow in Alias and Elektra in Marvel films, where she faced tough adversaries.
Current Challenge: The actress is now dealing with the challenges posed by unpredictable investors in her entrepreneurial ventures.
Entrepreneurial Success: Despite the challenges, Garner appears to be successfully navigating the investment landscape.
Transition from Acting to Business: Garner's shift from acting to entrepreneurship highlights her versatility and determination in facing new challenges.
See More
SpyGlass Pharma and Agomab's Contrasting Nasdaq Debuts
- SpyGlass Pharma's Strong Performance: SpyGlass Pharma (SGP) opened at $24.00 on its Nasdaq debut, reflecting a 50% increase from its IPO price of $16.00, and surged to $26.00 during trading, indicating a 63% rise, showcasing strong market interest in its ocular treatment candidates.
- Agomab Therapeutics Decline: In contrast, Agomab Therapeutics (AGMB) opened at $14.70, representing an ~8% drop from its IPO price, and fell further to $14.00, marking a 13% decline, indicating cautious market sentiment towards its immunology and inflammatory disease treatments.
- Significant Fundraising: The two companies priced their offerings late Thursday to raise a combined total of $350 million in gross proceeds, reflecting ongoing investor interest and enthusiasm in the biotech sector.
- Market Volatility Impact: SpyGlass's stock was halted for volatility but quickly rebounded, indicating investor confidence in its growth potential, while Agomab's continued decline may affect its future fundraising and market performance.
See More
SpyGlass Pharma and Agomab IPO Pricing Announced
- SpyGlass Pharma IPO: SpyGlass Pharma (SGP) is set to begin trading on Nasdaq after pricing its IPO at $16.00 per share for 9.375 million shares, aiming to raise approximately $150 million to fund phase 3 trials for its Bimatoprost Drug Pad-IOL System, with data expected in 2027, highlighting its potential in glaucoma treatment.
- Agomab Therapeutics Offering: Belgian biotech Agomab Therapeutics (AGMB) also priced its offering at $16.00 per share for 12.5 million American Depositary Shares, targeting $200 million in gross proceeds to support a Phase 2b trial for its drug ontunisertib, aimed at treating fibrostenosing Crohn’s disease, set to begin in H2 2026.
- Positive Market Response: The combined expected proceeds of $350 million from both companies reflect strong investor interest in the biotech sector, particularly in innovative drug development for ophthalmology and gastrointestinal diseases.
- Clinical Trial Prospects: The clinical-stage candidates from SpyGlass and Agomab present significant market opportunities, as successful trials could enhance their competitiveness in the biopharmaceutical industry and attract further investment.
See More
AgomAb Therapeutics Raises $200 Million in IPO for Fibrotic Disorder Therapies
- Funding Achievement: AgomAb Therapeutics successfully raised $200 million by offering 12.5 million shares at $16 each, priced at the midpoint of the $15 to $17 range, indicating strong market demand for its innovative therapies.
- Market Valuation: Following this financing, AgomAb commands a fully diluted market value of $875 million, reflecting investor confidence in its potential within the chronic fibrotic disease market, particularly given the high unmet medical needs.
- Product Pipeline: The lead product candidate, ontunisertib (AGMB-129), is a selective oral small molecule inhibitor targeting Fibrostenosing Crohn’s Disease, showcasing promising clinical prospects and potentially offering new treatment options for patients.
- Future Plans: The company plans to list on Nasdaq under the ticker AGMB, which is expected to enhance its market visibility and provide funding for further research and market development.
See More
Agomab Therapeutics Prices IPO at $16 per ADS
- IPO Pricing Announcement: Agomab Therapeutics has priced its initial public offering (IPO) at $16 per American Depositary Share (ADS), with expected gross proceeds of $200 million, reflecting strong market demand for its chronic fibrotic therapies.
- Underwriter Option: The company has granted underwriters a 30-day option to purchase an additional 1,875,000 ADSs at the IPO price, a strategy aimed at enhancing fundraising capabilities and meeting potential investor demand.
- Exchange Listing Plans: Agomab's ADSs are expected to begin trading on the Nasdaq Global Select Market on February 6, 2026, marking a significant milestone for the company in the biopharmaceutical sector and potentially attracting more investor interest in its innovative therapies.
- Underwriter Lineup: J.P. Morgan, Morgan Stanley, Leerink Partners, and Van Lanschot Kempen are acting as joint book-running managers for the offering, demonstrating market confidence in Agomab and its potential in the biopharmaceutical industry.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Updates: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting the latest market perspectives and expectations for these firms.
- Market Dynamics Overview: While specific company names are not mentioned, changes in analyst ratings typically influence investor decisions, potentially leading to price fluctuations in the related stocks.
- Investor Considerations: For those considering buying AMLX stock, analysts' opinions will serve as a crucial reference point, potentially impacting their investment strategies and market confidence.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions, although specific rating details are not disclosed.
See More
Jennifer Garner's Once Upon a Farm Sees Nearly 20% Increase as IPO Week Concludes
Jennifer Garner's Characters: Garner is known for her roles as Sidney Bristow in Alias and Elektra in Marvel films, where she faced tough adversaries.
Current Challenge: The actress is now dealing with the challenges posed by unpredictable investors in her entrepreneurial ventures.
Entrepreneurial Success: Despite the challenges, Garner appears to be successfully navigating the investment landscape.
Transition from Acting to Business: Garner's shift from acting to entrepreneurship highlights her versatility and determination in facing new challenges.
See More
SpyGlass Pharma and Agomab's Contrasting Nasdaq Debuts
- SpyGlass Pharma's Strong Performance: SpyGlass Pharma (SGP) opened at $24.00 on its Nasdaq debut, reflecting a 50% increase from its IPO price of $16.00, and surged to $26.00 during trading, indicating a 63% rise, showcasing strong market interest in its ocular treatment candidates.
- Agomab Therapeutics Decline: In contrast, Agomab Therapeutics (AGMB) opened at $14.70, representing an ~8% drop from its IPO price, and fell further to $14.00, marking a 13% decline, indicating cautious market sentiment towards its immunology and inflammatory disease treatments.
- Significant Fundraising: The two companies priced their offerings late Thursday to raise a combined total of $350 million in gross proceeds, reflecting ongoing investor interest and enthusiasm in the biotech sector.
- Market Volatility Impact: SpyGlass's stock was halted for volatility but quickly rebounded, indicating investor confidence in its growth potential, while Agomab's continued decline may affect its future fundraising and market performance.
See More
SpyGlass Pharma and Agomab IPO Pricing Announced
- SpyGlass Pharma IPO: SpyGlass Pharma (SGP) is set to begin trading on Nasdaq after pricing its IPO at $16.00 per share for 9.375 million shares, aiming to raise approximately $150 million to fund phase 3 trials for its Bimatoprost Drug Pad-IOL System, with data expected in 2027, highlighting its potential in glaucoma treatment.
- Agomab Therapeutics Offering: Belgian biotech Agomab Therapeutics (AGMB) also priced its offering at $16.00 per share for 12.5 million American Depositary Shares, targeting $200 million in gross proceeds to support a Phase 2b trial for its drug ontunisertib, aimed at treating fibrostenosing Crohn’s disease, set to begin in H2 2026.
- Positive Market Response: The combined expected proceeds of $350 million from both companies reflect strong investor interest in the biotech sector, particularly in innovative drug development for ophthalmology and gastrointestinal diseases.
- Clinical Trial Prospects: The clinical-stage candidates from SpyGlass and Agomab present significant market opportunities, as successful trials could enhance their competitiveness in the biopharmaceutical industry and attract further investment.
See More
AgomAb Therapeutics Raises $200 Million in IPO for Fibrotic Disorder Therapies
- Funding Achievement: AgomAb Therapeutics successfully raised $200 million by offering 12.5 million shares at $16 each, priced at the midpoint of the $15 to $17 range, indicating strong market demand for its innovative therapies.
- Market Valuation: Following this financing, AgomAb commands a fully diluted market value of $875 million, reflecting investor confidence in its potential within the chronic fibrotic disease market, particularly given the high unmet medical needs.
- Product Pipeline: The lead product candidate, ontunisertib (AGMB-129), is a selective oral small molecule inhibitor targeting Fibrostenosing Crohn’s Disease, showcasing promising clinical prospects and potentially offering new treatment options for patients.
- Future Plans: The company plans to list on Nasdaq under the ticker AGMB, which is expected to enhance its market visibility and provide funding for further research and market development.
See More
Agomab Therapeutics Prices IPO at $16 per ADS
- IPO Pricing Announcement: Agomab Therapeutics has priced its initial public offering (IPO) at $16 per American Depositary Share (ADS), with expected gross proceeds of $200 million, reflecting strong market demand for its chronic fibrotic therapies.
- Underwriter Option: The company has granted underwriters a 30-day option to purchase an additional 1,875,000 ADSs at the IPO price, a strategy aimed at enhancing fundraising capabilities and meeting potential investor demand.
- Exchange Listing Plans: Agomab's ADSs are expected to begin trading on the Nasdaq Global Select Market on February 6, 2026, marking a significant milestone for the company in the biopharmaceutical sector and potentially attracting more investor interest in its innovative therapies.
- Underwriter Lineup: J.P. Morgan, Morgan Stanley, Leerink Partners, and Van Lanschot Kempen are acting as joint book-running managers for the offering, demonstrating market confidence in Agomab and its potential in the biopharmaceutical industry.
See More
